About: Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria
Creator	Davies, Nigel Kam, Satu Marshall, Elena Penwarden, Alison Riga, Paraskevi Robertson, Matt
Source	Medline; PMC
abstract	INTRODUCTION: To measure the prevalence of hydroxychloroquine retinopathy in patients attending a hydroxychloroquine monitoring service using 2018 Royal College of Ophthalmologists diagnostic criteria. METHODS: A service evaluation audit of a hydroxychloroquine retinopathy monitoring service was undertaken. Results of Humphrey 10–2 field tests, spectral-domain optical coherence tomography and fundus autofluorescence were collected with data on dose, weight, duration of treatment, estimated glomerular filtration rate, and concurrent tamoxifen therapy. Visual field tests were assessed as reliable or unreliable, and classified as normal, hydroxychloroquine-like, poor test or related to other pathology. Cases of definite and possible retinopathy were identified using the 2018 RCOphth criteria. RESULTS: There were 1976 attendances over two years of 1597 patients. Seven hundred and twenty-eight patients had taken hydroxychloroquine for less than 5 years and 869 had taken hydroxychloroquine for 5 years or more. Fourteen patients were identified with definite hydroxychloroquine retinopathy (1.6%), and 41 patients with possible retinopathy (4.7%). Sixty-seven per cent of 861 visual fields were performed reliably, with 66.9% classified as normal, 24.9% as poor test, 5.2% hydroxychloroquine-like and 3.0% abnormal due to other pathology. CONCLUSIONS: The 1.6% prevalence of hydroxychloroquine retinopathy is lower than the previously reported prevalence of 7.5% as reported by Melles and Marmor JAMA Ophthalmol 132: 1453–60 (2014). This is because of a difference in the diagnostic criteria. Both definite and possible retinopathy would meet the diagnostic criteria of the Melles and Marmor study; 6.3% in our data, compared with 7.5%, a much smaller difference and likely to be explained by differences in the risk characteristics of the two groups.
has issue date	2020-06-25(xsd:dateTime)
bibo:doi	10.1038/s41433-020-1038-2
bibo:pmid	32587388
has license	no-cc
sha1sum (hex)	fd664328c488fb3d61b596037a17090c14e95c9b
schema:url	https://doi.org/10.1038/s41433-020-1038-2
resource representing a document's title	Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria
has PubMed Central identifier	PMC7316164
has PubMed identifier	32587388
schema:publication	Eye (Lond)
resource representing a document's body	covid:fd664328c488fb3d61b596037a17090c14e95c9b#body_text
is schema:about of	named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'retinopathy' named entity 'tamoxifen' named entity 'optical coherence tomography' named entity 'retinopathy' named entity 'hydroxychloroquine' named entity 'Melles' named entity 'hydroxychloroquine' named entity 'retinopathy' named entity 'statistical significance' named entity 'antiviral' named entity 'visual field' named entity 'Prospective studies' named entity 'anti-inflammatory' named entity 'Student's t test' named entity 'toxicity' named entity 'retinopathy' named entity 'hydroxychloroquine' named entity 'hepatic dysfunction' named entity 'immunomodulatory' named entity 'Bonferroni correction' named entity 'retinopathy' named entity 'systemic disease' named entity 'renal failure' named entity 'clinical findings' named entity 'visual field test' named entity 'anatomy' named entity 'visual fields' named entity 'pathology' named entity 'optical coherence tomography' named entity 'toxicity' named entity 'Springer Nature' named entity 'pregnancy' named entity 'hydroxychloroquine' named entity 'toxicity' named entity 'hydroxychloroquine' named entity 'retinopathy' named entity 'scotoma' named entity 'retinal ganglion cells' named entity 'toxicity' named entity 'anatomy' named entity 'field test' named entity 'cinchona tree' named entity 'hydroxychloroquine' named entity 'HCQ' named entity 'outer nuclear layer' named entity 'retinopathy' named entity 'retinopathy' named entity 'retinopathy' named entity 'fundus' named entity 'statistically significantly' named entity 'HCQ' named entity 'SLE' named entity 'HCQ' named entity 'Visual field' named entity 'visual field test' named entity 'anatomical' named entity 'scotoma' named entity 'HCQ' named entity 'toxicity' named entity 'toxicity' named entity 'electronic patient record' named entity 'anti-proliferative' named entity 'toxicity' named entity 'HCQ' named entity 'statistical significance' named entity 'arterial stiffness' named entity 'toxicity' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'St Thomas' Hospital' named entity 'toxicity' named entity 'hydroxychloroquine' named entity 'Royal College of Ophthalmologists' named entity 'field defects'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software